Erythromycin Ethylsuccinate

• UNSPSC Description:

  Erythromycin Ethylsuccinate is an antibiotic useful for the treatment of a number of bacterial infections, has an antimicrobial spectrum similar to or slightly wider than that of penicillin. Erythromycin Ethylsuccinate has antiviral activity against HIV-1.

• Target Antigen:

  Antibiotic; Autophagy; Bacterial; HIV

• Type:

  Natural Products

• Related Pathways:

  Anti-infection;Autophagy

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/Erythromycin-Ethylsuccinate.html

• Purity:

  98.0

• Solubility:

  DMSO : ≥ 50 mg/mL|Ethanol : ≥ 33.33 mg/mL

• Smiles:

  O=C(CCC(OCC)=O)O[C@H]([C@H]1N(C)C)[C@](O[C@H](C)C1)([H])O[C@@H]([C@](O)(C[C@H](C([C@@H]([C@@H](O)[C@@]2(O)C)C)=O)C)C)[C@H]([C@@H]([C@H](C(O[C@@H]2CC)=O)C)O[C@@](O[C@@H](C)[C@@H]3O)([H])C[C@@]3(C)OC)C

• Molecular Weight:

  862.05

• References & Citations:

  [1]Gustafsson A, et al. The association of erythromycin ethylsuccinate with acute colitis in horses in Sweden. Equine Vet J. 1997 Jul;29(4):314-8.|[2]Feng YC, et al. Construction of universal quantitative models for determination of roxithromycin and erythromycin ethylsuccinate in tablets from different manufacturers using near infrared reflectance spectroscopy. J Pharm Biomed Anal. 2006 May 3;41(2):373-84.|[3]Komuro I, et al. Erythromycin derivatives inhibit HIV-1 replication in macrophages through modulation of MAPK activity to induce small isoforms of C/EBPbeta. Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12509-14.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  1264-62-6